Last reviewed · How we verify
NCT04982484: PAMER
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
trial in Ophthalmopathy in 50 participants. Completed in 1 August 2013.
1 June 2013
Quick facts
| Lead sponsor | Centre Hospitalier Régional Metz-Thionville |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 September 2010 |
| Primary completion | 1 June 2013 |
| Estimated completion | 1 August 2013 |
Conditions studied
- Ophthalmopathy — all drugs for Ophthalmopathy →
- Wet Macular Degeneration — all drugs for Wet Macular Degeneration →
Sponsor
Centre Hospitalier Régional Metz-Thionville
Who can join
20 and older, any sex, with Ophthalmopathy or Wet Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
AMD (age-related macular degeneration), is the leading cause of blindness in individuals over the age of 55. There is no cure for wet-AMD but anti-VEGF treatments significantly minimize the vision loss over time. To study the correlation between anti-VEGF injection bevacizumab (Lucentis), visual acuity, macular thickness and last but not least reading speed in wet-AMD patients. The study was conducted on 50 eyes of 50 wet-AMD patients. Subjects were monthly treated with an intra-vitreal Lucentis injection for 3 months; further injections were given when a loss of 5 or more letters of visual acuity was observed and/or when the retinal thickness in the affected macular area increased by 100 µm. In addition to a full ophthalmological examination reading speed was investigated via the Radner reading chart before and 3 months after treatment. The collected data was analyzed using paired t-tests.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04982484
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ophthalmopathy
Currently open trials in the same condition.
- NCT05414994 — Assessment of the Ocular Microbiome in Health and Disease · recruiting
- NCT06367517 — Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) · recruiting
Other Centre Hospitalier Régional Metz-Thionville trials
Trials by the same sponsor.
- NCT07435389 — VENTILATION DURING SPACEFLIGHT (PHASE 2) · NA · not yet recruiting
- NCT07405996 — Referral of Patients With Biological Abnormalities to an Emergency Department · not yet recruiting
- NCT07406022 — Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. · not yet recruiting
- NCT07515404 — A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study · completed
- NCT07390604 — Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patien · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04982484 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional Metz-Thionville
- Last refreshed: 29 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04982484.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing